FDA enforcement is unpredictable
A single FDA Warning Letter can wipe a peptide brand. Most agencies cannot model that risk.
Marketing for peptide brands, SARMs retailers, and research-compound stores.
Helping you sell research chemicals in a way that makes people return for more, from basic BPC-157 to cutting-edge formulations. Get the most out of the peptides trend while it lasts.
Get in touch →80+ warmed accounts on Evolutionary.org, Meso-Rx, AnabolicMinds, Looksmax.org, and Mewing.coach.
Direct reach into the communities driving 70%+ of peptide purchase decisions
PBN of 35+ sports, biohacking, longevity, and men’s-health domains.
Compounding domain authority on a category most link networks reject outright
Email deliverability stack on peptide-tolerant ESPs with dedicated IP warming.
Inbox placement on a category most ESPs filter or bounce on first import
Network of peptide-friendly fitness, biohacking, and longevity creators.
Influencer-driven reach independent of mainstream platform tolerance
A single FDA Warning Letter can wipe a peptide brand. Most agencies cannot model that risk.
PayPal, Stripe, and major processors will not underwrite peptide MCC. Specialised processors and crypto rails are the alternatives.
Meta, Google, TikTok all refuse peptide advertising regardless of "research-use-only" framing.
Most ESPs filter peptide-related keywords aggressively. Direct messaging requires specialised infrastructure.
The buyer-intent search demand for peptides is real, direct, and largely under-served by operators who do not invest in marketing infrastructure. The data below illustrates the categories your customers are already searching for. Ranking, paid placement, and direct-channel presence on these queries are direct revenue.
| Buyer-intent keyword | Monthly search volume |
|---|---|
| buy peptides online | 12,100/mo |
| best peptide companies | 4,400/mo |
| sarms for sale | 14,800/mo |
| bpc-157 dosage | 40,500/mo |
Local, eCom, parasite, PBN, negative-defense.
SVC-002Paid acquisition across compliant platforms and gray-market networks.
SVC-003Press, suppression, review management, crisis communication.
SVC-004Forum, Reddit, Discord, Telegram. Community-driven reach where it matters.
SVC-005Funnel, retention, upsell, conversion rate optimization.
SVC-006Conversion-tuned brand and store sites. Built for the vertical.
SVC-007Niche-fluent copy and editorial that respects the audience.
SVC-008Strategy, audits, contingency planning, founder advisory.
Their forum-account roster placed our brand into peptide-buyer conversations from week one. Saved us nine months of community-building work.
They had warm intros to two processors I had been chasing for six months. Both underwrote inside the first week.
The third-party testing documentation they helped us standardise became our biggest conversion lift on the PDP. Trust as a feature.
That is the way you are expected to market them. Pushing the research narrative too hard, though, scares away your clients. Creating content about peptides that sells AND avoids triggering suppression or removal is an art we have polished over the last year.
Most early-stage peptide brands need foundation work — site, deliverability, payment infrastructure — before any growth marketing makes sense. The audit identifies what to build first; the retainer builds it.
SARMs are an outgoing trend. The customer base still exists, but the curve is pointing down. Peptides are on the rise, with new compounds entering retail every quarter and the audience expanding. We treat peptides as the more competitive of the two and calibrate engagement intensity accordingly.
Yes. Influencer networks (fitness, biohacking, longevity), forum and Reddit-adjacent organic, peptide-friendly ad networks, and email/SMS direct channels. Most peptide acquisition runs outside mainstream platforms anyway.
Most engagements start with a three-week audit. The form below tells us enough to scope the call. Or write directly: contacts@despitemarketing.com. Your brief goes straight to a partner, not a triage queue.